menu
    • menu
    [{"orgOrder":0,"company":"Nazarbayev University Medical Center","sponsor":"Eurasia Invest | Ministry of Education and Science, Kazakhstan","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"KAZAKHSTAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Nazarbayev University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nazarbayev University Medical Center \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan","highestDevelopmentStatusID":"1","companyTruncated":"Nazarbayev University Medical Center \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"}]

    Find Clinical Drug Pipeline Developments & Deals for Ceftin

    Menu

    Ceftin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GSK

                            United Kingdom arrow
                            Florida Innovation
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sandoz Completes Acquisition of GSK’s Cephalosporin Business, Reinforcing Leading Global Position in Antibio...

                            Details : Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.

                            Product Name : Zinnat

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            October 11, 2021

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GSK

                            United Kingdom arrow
                            Florida Innovation
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : $500.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            GSK to Sell Cephalosporin Antibiotics Business to Sandoz

                            Details : Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.

                            Product Name : Zinnat

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            February 11, 2021

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : $500.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Korea United Pharm. Inc.

                            South Korea arrow
                            Florida Innovation
                            Not Confirmed

                            Korea United Pharm. Inc.

                            South Korea arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis

                            Details : Cefuroxime is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nazarbayev University Medical Center

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Nazarbayev University Medical Center

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : Eurasia Invest | Ministry of Education and Science, Kazakhstan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics

                            Details : Cefuroxime is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Bronchitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2018

                            Lead Product(s) : Cefuroxime Axetil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Eurasia Invest | Ministry of Education and Science, Kazakhstan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth